LLGL2 and cancer: In recent years, aberrant localization and/or reduced expression for either HUGLl or HUGL2 have been reported in several epithelial cancers including cancer of the breast, stomach, colon, ovary, prostate, skin, endometrium, oesophageal, lung and glioma (Grifoni et al., 2004; Imamura et al., 2013; Kuphal et al., 2006; Lisovsky et al., 2009, 2010; Liu et al., 2015; Matsuzaki et al., 2015; Nam et al., 2014; Schimanski et al., 2005; Song et al., 2013; Spaderna et al., 2008; Tsuruga et al., 2007).